- Eliquis global operational revenue up $513M (25%) driven by higher net price in U.S. and higher demand globally.
Pfizer reported Q3 2026 operational revenue growth driven by Eliquis, Padcev, Vyndaqel, Nurtec, and Lorbrena, offset by declines in Paxlovid, Comirnaty, and Prevnar. R&D expenses rose 18% operationally. Recent developments include FDA approval for updated COVID vaccine and Phase 3 results for Elrexfio.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.